Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayeasian network meta-analysis

Victor Hugo Fonseca de Jesus and Rachel P Riechelmann

ecancer 15 1276 (2021)

Medical Oncology Department, A.C. Camargo Cancer Center, Rua Prof. Antônio Prudente 211, São Paulo SP 01509-010, Brazil

Throughout the text, please consider that the primary outcome of the PRODIGE24 trial was disease-free survival, and not overall survival.

Keywords: FOLFIRINOX, gemcitabine, capecitabine, nab-paclitaxel, adjuvant, pancreatic, cancer

Correspondence to: Victor Hugo Fonseca de Jesus

Published: 12/10/2021
Received: 23/09/2021

Publication costs for this article were supported by ecancer (UK Charity number 1176307).

Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Funding source

This study had no funding source.

Authors’ contributions

Victor Hugo Fonseca de Jesus: conceptualisation, methodology, data curation, data analyses, writing and visualisation; Rachel Pimenta Riechelmann: methodology, writing and visualisation.


Related Articles

Jemma Arakelyan, Alisa Movsisyan, Lilit Sargsyan, Armine Chopikyan, Diana Andreasyan, Arevik Torosyan, Ruzanna Papyan, Hovhannes Vardevanyan, Samvel Bardakhchyan, Artashes Tadevosyan, Gevorg Tamamyan, Armen Tananyan, Samvel Danielyan, Dickran Kazandjian
Eduardo Payet, Joan Perez, Gustavo Sarria, Silvia Neciosup, Francisco Berrospi, Sheila Vilchez, Jorge Dunstan, Ronald Perez, Mauricio Vassallo, Santiago Salgado, Nanto Caparachín, Joseph A Pinto, Alexis Holguin